ArticleFrontiers in cellular neuroscience2016
E2 Regulates Epigenetic Signature on Neuroglobin Enhancer-Promoter in Neuronal Cells.
Article in Frontiers in cellular neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Neuroglobin: A New Player in the Gut-Brain Axis.International journal of molecular sciences · 2026Review
- Epimedin C: A promising neuroprotective agent that can participate in mediating the JNK/Nrf2/HO-1 signaling pathway to prevent neurodegenerative diseases.Experimental and therapeutic medicine · 2026Article
- Detection of neuroglobin in umbilical cord blood signals progress in perinatal medicine.Scientific reports · 2025Article
- Neuroglobin and Cytoglobin in Mammalian Nervous Systems: About Distribution, Regulation, Function, and Some Open Questions.Brain sciences · 2025Review
- Role of Neuroglobin in the Neuroprotective Actions of Estradiol and Estrogenic Compounds.Cells · 2021Review
- Lessons from the post-genomic era: Globin diversity beyond oxygen binding and transport.Redox biology · 2020Review
- Neuroglobin Expression in the Brain: a Story of Tissue Homeostasis Preservation.Molecular neurobiology · 2019Review
- Neuroglobin Expression Models as a Tool to Study Its Function.Oxidative medicine and cellular longevity · 2019Review
- Estradiol and the Development of the Cerebral Cortex: An Unexpected Role?Frontiers in neuroscience · 2018Review
- Outlook on the neuroprotective effect of estrogen.Neural regeneration research · 2017Article
- Correlation Between Expression of Recombinant Proteins and Abundance of H3K4Me3 on the Enhancer of Human Cytomegalovirus Major Immediate-Early Promoter.Molecular biotechnology · 2017Article
- Protection by Neuroglobin Expression in Brain Pathologies.Frontiers in neurology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogens are neuroprotective factors in several neurological diseases. Neuroglobin (NGB) is one of the estrogen target genes involved in neuroprotection, but little is known about its transcriptional regulation. Estrogen genomic pathway in gene expression regulation is mediated by estrogen receptors (ERα and ERβ) that bind to specific regulatory genomic regions. We focused our attention on 17β-estradiol (E2)-induced NGB expression in human differentiated neuronal cell lines (SK-N-BE and NT-2). Previously, using bioinformatics analysis we identified a putative enhancer in the first intron of NGB locus. Therefore, we observed that E2 increased the enrichment of the H3K4me3 epigenetic marks at the promoter and of the H3K4me1 and H3K27Ac at the intron enhancer. In these NGB regulatory regions, we found estrogen receptor alpha (ERα) binding suggesting that ERα may mediate chromatin remodeling to induce NGB expression upon E2 treatment. Altogether our data show that NGB expression is regulated by ERα binding on genomic regulatory regions supporting hormone therapy applications for the neuroprotection against neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.